Skip to main content
. Author manuscript; available in PMC: 2015 Apr 1.
Published in final edited form as: J Am Acad Dermatol. 2014 Apr;70(4):621–629. doi: 10.1016/j.jaad.2014.01.857

Fig 4.

Fig 4

Pooled effect size and 95% confidence intervals for immunosuppressed tumors versus immunocompetent tumors (Hypothesis 2), showing that SCC from immunosuppressed patients are more likely to carry HPV than SCC from immunocompetent patients (pooled ES 3.01, 95%CI 2.00–4.52, p<0.0001). I2 and Q statistics showed minimal evidence of heterogeneity (I2=28.4%, Q = 15.37 (d.f. = 11) p = 0.17).